Pfizer Inc. $PFE Shares Sold by Lionshead Wealth Management LLC

Lionshead Wealth Management LLC lessened its position in Pfizer Inc. (NYSE:PFE) by 8.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 24,684 shares of the biopharmaceutical company’s stock after selling 2,320 shares during the period. Lionshead Wealth Management LLC’s holdings in Pfizer were worth $625,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of PFE. Clarity Asset Management Inc. acquired a new position in shares of Pfizer in the fourth quarter valued at approximately $27,000. Gould Capital LLC increased its position in Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 493 shares during the last quarter. GKV Capital Management Co. Inc. acquired a new position in Pfizer during the first quarter worth approximately $27,000. North Capital Inc. acquired a new position in Pfizer during the first quarter worth approximately $28,000. Finally, Bayforest Capital Ltd acquired a new position in Pfizer during the first quarter worth approximately $28,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of PFE stock opened at $25.8250 on Friday. The company has a market capitalization of $146.83 billion, a PE ratio of 13.74, a price-to-earnings-growth ratio of 0.92 and a beta of 0.52. The firm has a fifty day simple moving average of $24.70 and a 200-day simple moving average of $24.42. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. Pfizer’s dividend payout ratio is 91.49%.

Analyst Upgrades and Downgrades

Several brokerages recently commented on PFE. Berenberg Bank dropped their price target on shares of Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a research report on Thursday, May 29th. Leerink Partners dropped their price target on shares of Pfizer from $28.00 to $26.00 and set a “market perform” rating for the company in a research report on Wednesday, April 30th. UBS Group increased their price objective on shares of Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 30th. Citigroup increased their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Finally, The Goldman Sachs Group increased their price objective on shares of Pfizer from $25.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 30th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.